When implementing the ExoDx™ Prostate test in a real-world clinical setting, patients demonstrated improved compliance with the physician's recommendation to defer prostate biopsy when the test was ...
Medicare Issues Final Local Coverage Decision For Bio-Techne's ExoDx(TM) Prostate(IntelliScore) Test
MINNEAPOLIS, Oct. 10, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that the Medicare Administrative Contractor (MAC) National Government Services, Inc. issued a final ...
ExoDx Prostate (IntelliScore) is a clinically validated, non-digital rectal exam (DRE) urine-based liquid biopsy test that predicts the presence of high-grade (Gleason score ≥7) prostate cancer for ...
Dr. Keith Roach writes a medical question-and-answer column weekdays. Dear Dr. Roach: Due to an elevated PSA (5.3) my urologist recommended a fairly new test prior to deciding on a prostate biopsy.
Bio-Techne Receives Approval To Offer The ExoDx™ Prostate Intelliscore™ (EPI) Test In New York State
MINNEAPOLIS, June 13, 2019 /PRNewswire/ -- Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate ...
MINNEAPOLIS, May 7, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced a major publication in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical Utility of ...
MINNEAPOLIS, May 7, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced a major publication in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical Utility of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results